S
Shah Alam Khan
Researcher at National University of Science and Technology
Publications - 137
Citations - 4169
Shah Alam Khan is an academic researcher from National University of Science and Technology. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 24, co-authored 117 publications receiving 2817 citations. Previous affiliations of Shah Alam Khan include Oman Medical College & St. Joseph's Hospital and Medical Center.
Papers
More filters
Journal ArticleDOI
A review on therapeutic potential of Nigella sativa: A miracle herb
Aftab Ahmad,Asif Husain,Mohd Mujeeb,Shah Alam Khan,Abul Kalam Najmi,Nasir Ali Siddique,Zoheir A. Damanhouri,Firoz Anwar +7 more
TL;DR: A detailed survey of the literature on scientific researches of pharmacognostical characteristics, chemical composition and pharmacological activities of the seeds of this plant is provided.
Journal ArticleDOI
Essential oils used in aromatherapy: A systemic review
TL;DR: This review explores the information available in the literature regarding therapeutic, medical, cosmetic, psychological, olfactory, massage aromather therapy, safety issues and different plants used in aromatherapy.
Journal ArticleDOI
Estimation of total phenolic content, in–vitro antioxidant and anti–inflammatory activity of flowers of Moringa oleifera
TL;DR: The results of this study suggest that flowers of M. oleifera possess potent anti-inflammatory activity and are also a good source of natural antioxidants.
Journal ArticleDOI
GC-MS analysis, determination of total phenolics, flavonoid content and free radical scavenging activities of various crude extracts of Moringa peregrina (Forssk.) Fiori leaves
TL;DR: In this paper, Moringa peregrina leaves were extracted exhaustively by Soxhlet with ethanol and then fractionated into hexane, chloroform, ethy alacetate and methanol.
Journal ArticleDOI
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Mohd. Imran,Mandeep Kumar Arora,Syed Mohammed Basheeruddin Asdaq,Shah Alam Khan,Saleh I. Alaqel,Mohammed Kanan Alshammari,Mohammed M. Alshehri,Ahmed Subeh Alshrari,Alreshidi Mateq Ali,Ahmed Muteb Al-Shammeri,Bushra Dhuhayyan Alhazmi,Aishah Ali Harshan,Tauquir Alam +12 more
TL;DR: Molnupiravir as mentioned in this paper, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19 and has shown good safety profile, tolerability, and oral bioavailability in humans.